Clinical trials: Streptococcus Pneumoniae Infections
Pneumococcal Infections
Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly
The purpose of this study is to evaluate the immunogenicity and safety of an investigational 23-valent pneumococcal polysaccharide vaccine (PPV) in healthy children, adults and elderly.
- Trial name
- NCT02451969
- Testing
- investigational 23-valent PPV, control 23-valent PPV
- Where
- China
- Volunteers
- 1,760 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
CKD (Chronic Kidney Disease) Stage 5D, Pneumonia
Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients
The investigators compare two strata of vaccinated patients: those recently vaccinated and those vaccinated more than two years ago. The primary objective is to compare pneumonia rates between the groups.
- Trial name
- DOPPIO (NCT03350425)
- Where
- 12 sites in Germany
- Volunteers
- 792 people
- Sponsor
- University of Cologne
Pneumococcal Infections, Streptococcus Pneumoniae
Immunogenicity of PCV-7 Vaccine in VLBW Infants
Premature infants are at a high risk for pneumonia. The PCV-7 vaccine effectively prevents the invasive disease from Streptococcus pneumoniae in full-term infants, but was not thoroughly studied in premature infants.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae, Infant, Newborn, Infant, Low Birth Weight
- Trial name
- PCV-7 (NCT00273325)
- Where
- 10 sites in United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- NICHD Neonatal Research Network
Pneumococcal Meningitis
Study Evaluating Pneumococcal Meningitis in the Paediatric Population in Spain Four Years After the Marketing of Prevenar.
The aim of this study is to determine the prevalence of pneumococcal meningitis in the paediatric population in Spain four years after the marketing of Prevenar.
- Trial name
- NCT00227214
- Where
- 39 sites in Spain
- Volunteers
- 160 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infection, Pneumococcal Infections
Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults
S. pneumoniae is frequently isolated from nasal swabs of healthy subjects, but it can also cause severe diseases (pneumonia, bacteraemia, meningitis and sepsis).HIV-infected subjects are more sensitive to invasive diseases and…
- Trial name
- PCV13HIV2011 (NCT02123433)
- Testing
- pneumococcal conjugate 13 valent vaccine
- Where
- 2 sites in Italy
- Volunteers
- 50 people
- Sponsor
- University of Siena
Pneumonia, Pneumococcal
Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
The purpose of this study is to evaluate Immunogenicity and safety of 23-Valent Pneumococcal Polysaccharide Vaccine in healthy volunteers aged 2 Years and above.
- Trial name
- NCT04278248
- Testing
- 23-Valent Pneumococcal Polysaccharide Vaccine
- Where
- China
- Volunteers
- 1,940 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Pneumococcal Infections
Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine
This is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunogenicity…
- Trial name
- NCT05477693
- Testing
- Experimental 23-valent PPV, Control 23-valent PPV
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
- Trial name
- NCT00743652
- Testing
- 13-valent Pneumococcal Conjugate Vaccine
- Where
- 21 sites in United States
- Volunteers
- 373 people, healthy volunteers welcome
- Sponsor
- Pfizer
Community-acquired Pneumonia
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
I. To investigate time measurement from emergency room admission to first antibiotic administration. II. To evaluate risk factors for prolonged time to first antibiotic administration. III.
- Trial name
- NCT01683487
- Testing
- Observation
- Where
- Switzerland
- Volunteers
- 122 people
- Sponsor
- University of Zurich
Acellular Pertussis, Tetanus
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
Booster and immune memory study
- Conditions
- Acellular Pertussis, Tetanus, Hepatitis B, Diphtheria
- Trial name
- NCT00307567
- Testing
- Pneumococcal (vaccine)
- Where
- 51 sites in Germany
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Infections
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
The purpose of this study is 1) to evaluate the safety and tolerability of V114 with respect to the proportion of participants with adverse events (AEs) and 2) to evaluate the anti-pneumococcal polysaccharide (PnPs)…
- Trial name
- PNEU-PLAN (NCT03885934)
- Testing
- V114, Prevnar 13®
- Where
- 26 sites in Finland, Malaysia and 3 more
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumococcal Vaccines
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 4 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving…
- Trial name
- NCT06720038
- Testing
- 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vaxcyte, Inc.
Pneumococcal Disease
Study Evaluating Prevenar in High-Risk Children
The purpose of this study is to estimate the local and systemic tolerability of Prevenar in children ages 2 to 5 years old in usual care settings.
- Trial name
- NCT00234338
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Influenza, Streptococcus Pneumoniae
Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years
Recent reviews have highlighted the unpredictability and complexity of immune interference when multivalent conjugate vaccines are co-administered with other pediatric vaccines.
- Trial name
- NCT02215863
- Testing
- Fluad and Prevenar13, Fluad, Prevenar13
- Where
- 3 sites in South Korea
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
HIV, Malaria
Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance
At least three studies in sub-Saharan Africa have demonstrated a decrease in morbidity or mortality among HIV-infected adults who took daily cotrimoxazole (trimethoprim sulfamethoxazole) [CTX] prophylaxis.
- Conditions
- HIV, Malaria, Diarrhea, Pneumonia
- Trial name
- NCT00137657
- Testing
- Cotrimoxazole (trimethoprim sulfamethoxazole)
- Where
- Kenya
- Volunteers
- 1,478 people
- Sponsor
- Centers for Disease Control and Prevention
Healthy Subjects, Pneumococcal Infections
Study Evaluating Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in healthy infants. This is the first study with this vaccine in infants.
- Trial name
- NCT00205803
- Testing
- 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pneumococcal Disease
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among adults, children, and infants, as well as the immunogenicity of 20vPnC among infants and children under 2 years…
- Trial name
- NCT07023081
- Testing
- 20vPnC, 13vPnC
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumonia, Pneumococcal
Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
To explore a further dimension of susceptibility to disease, the investigators tested the hypothesis that natural variation exists in the rapidity of IgG responses following exposure to pneumococcal polysaccharides, and that…
- Trial name
- NCT03460730
- Testing
- Pneumovax
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Pneumococcal Disease
Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.
- Trial name
- NCT01128426
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 53,902 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Infections, Meningococcal Infections
Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines
The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either…
- Trial name
- sched1 (NCT00197808)
- Testing
- menjugate, Men C conjugate vaccine, Men C conjugate
- Where
- 2 sites in United Kingdom
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Public Health England